Evidence map›Paper›PMID 41538289›Full record

ArticleJCI insight2026

Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition.

Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Mehri MonavarianDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birmingham, Alabama, USA.
Resha RajkarnikarDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birmingham, Alabama, USA.
Emily Faith PageDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birmingham, Alabama, USA.
Asha KumariDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birmingham, Alabama, USA.
Liz Quintero MaciasDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birmingham, Alabama, USA.
Felipe MassicanoUAB Biological Data Science Core, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Nam Y LeeDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.
Sarthak SahooDepartment of Bioengineering, Indian Institute of Science, Bangalore, India.
Nadine HempelDivision of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Mohit Kumar JollyDepartment of Bioengineering, Indian Institute of Science, Bangalore, India.
Lara IanovUAB Biological Data Science Core, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Elizabeth WortheyUAB Biological Data Science Core, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abhyudai SinghDepartment of Electrical and Computer Engineering, University of Delaware, Newark, Delaware, USA.
Igor B RoninsonDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
Eugenia V BroudeDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
Mengqian ChenDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
Karthikeyan MythreyeDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birmingham, Alabama, USA.

Funding

Preventing adaptive drug resistance through Mediator kinase inhibitionR01CA266027 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Hexin Chen, Mengqian Chen · 2022 to 2026
$3.0M
Generalized fluctuation test for deciphering phenotypic switching within cell populationsR35GM148351 · NIGMS · UNIVERSITY OF DELAWARE · PI Abhyudai Singh · 2023 to 2026
$1.6M
Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancerR41CA298223 · NCI · SENEX BIOTECHNOLOGY, INC. · PI CHEN, MENGQIAN, KARTHIKEYAN, MYTHREYE · 2025 to 2025
$400k
NCI NIH HHS R01 CA266027NCI NIH HHS R41 CA298223NIGMS NIH HHS R35 GM148351
6 · The paper itself

Abstract

Anoikis resistance, or evasion of cell death triggered by matrix detachment, is a hallmark of cancer cell survival and metastasis. We showed that repeated exposure to suspension stress followed by recovery under attached conditions leads to development of anoikis resistance. The acquisition of anoikis resistance was associated with enhanced invasion, chemoresistance, and immune evasion in vitro and distant metastasis in vivo. This acquired anoikis resistance was not genetic, persisting for a finite duration without detachment stress, but was sensitive to CDK8/19 mediator kinase inhibition that could also reverse anoikis resistance. Transcriptomic analysis revealed that CDK8/19 kinase inhibition induces bidirectional transcriptional changes in both sensitive and resistant cells, disrupting the balanced reprogramming required for anoikis adaptation and resistance by reversing some resistance-associated pathways and enhancing others. Both anoikis resistance and in vivo metastatic growth of ovarian cancers are sensitive to CDK8/19 inhibition, thereby providing a therapeutic opportunity to both prevent and suppress ovarian cancer metastasis.

Indexed as

AnoikisCyclin-Dependent Kinase 8Cyclin-Dependent KinasesOvarian NeoplasmsProtein Kinase InhibitorsAnimalsCell Line, TumorDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisCDK19 protein, humanCyclin-Dependent Kinase 8Cyclin-Dependent KinasesProtein Kinase InhibitorsApoptosis survival pathwaysCancerCell biologyCell stressOncology

Identifiers

PMID41538289
PMCPMC12956021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.